Focal adhesion kinase (FAK) is both a non-receptor tyrosine kinase and an adaptor protein
that primarily regulates adhesion signalling and cell migration, but FAK can also promote …

Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …

Cancer is one of the leading causes of human death, despite enormous efforts to explore
cancer biology and develop anticancer therapies. The main challenges in cancer research …

Integrins mediate cell adhesion and transmit mechanical and chemical signals to the cell
interior. Various mechanisms deregulate integrin signaling in cancer, empowering tumor …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Doxorubicin is utilized for anti-neoplastic treatment for several decades. The utility of this
drug is limited due to its side effects. Generally, doxorubicin toxicity is originated from the …

Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, is overexpressed and
activated in many cancer types. FAK regulates diverse cellular processes, including growth …

Single-agent immunotherapy has achieved limited clinical benefit to date in patients with
pancreatic ductal adenocarcinoma (PDAC). This may be a result of the presence of a …

Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed
and activated in several advanced-stage solid cancers. FAK promotes tumour progression …

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression
and metastasis but also has profound effects on therapeutic efficacy. In the case of …